Last checked at 2 Feb 2021 07:05
Destiny Pharma PLC
("Destiny" or "the Company")
Destiny Pharma to Participate in Panel Discussion at the
7th Annual LSX World Congress 2021
Brighton, UK, 2 February 2021 - Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening infections, announces that Neil Clark, Chief Executive Officer, will be taking part in a panel discussion at the 7th Annual LSX World Congress to be held virtually between 1-5 February, 2021.
The panel discussion 'Investing In Infectious Disease - How Will The Covid Pandemic Transform The Development, Commercialisation, And Partnering Landscape?' will be held at 15:00 GMT on 2nd February 2021.
The panel will be made available through the conference website and will be available to registered participants throughout the event - www.lsxleaders.com/lsx-world-congress.
- Ends -
Enquiries:
Destiny Pharma plc
+44 (0) 1273 704 440
Neil Clark (Chief Executive Officer)
Shaun Claydon (Chief Financial Officer and Company Secretary)
finnCap Limited - Nominated Adviser and Joint Broker
+44 (0) 20 7220 0500
Geoff Nash / Kate Bannatyne / Charlie Beeson (Corporate Finance)
Alice Lane (ECM)
WG Partners LLP - Joint Broker
+44 (0) 20 3705 9330
Nigel Barnes / Claes Spång / Nigel Birks / Andrew Craig
Optimum Strategic Communication
+44 (0) 203 174 1789
Mary Clark / Shabnam Bashir / Manel Mateus
About Destiny Pharma
Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which is in a Phase 2b clinical trial targeting the prevention of post-surgical Staphylococcal hospital infections including MRSA. It is also co-developing SPOR-COV, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF research projects.
For further information, please visit https://www.destinypharma.com